TPP1 Polyclonal Antibody

catalytic activity:Release of an N-terminal tripeptide from a polypeptide, but also has endopeptidase activity.,caution:Ref.3 sequence is wrongly reported to originate from bovine.,disease:Defects in TPP1 are the cause of classical late-infantile neuronal ceroid lipofuscinosis (LINCL) [MIM:204500]; also known as ceroid lipofuscinosis neuronal 2 (CLN2). LINCL is a fatal childhood neurodegenerative disease characterized by progressive visual and mental decline, motor disturbance, epilepsy and behavioral changes. The three main subtypes of childhood NCLs defined by the age of onset, clinical features, and ultrastructural morphology are infantile NCL (INCL), classical late-infantile NCL (LINCL), or juvenile NCL (JNCL), although a number of other distinct variants forms have been described.,function:Lysosomal serine protease with tripeptidyl-peptidase I activity. May act as a non-specific lysosomal peptidase which generates tripeptides from the breakdown products produced by lysosomal proteinases. Requires substrates with an unsubstituted N-terminus.,online information:Neural Ceroid Lipofuscinoses mutation db,PTM:Activated by autocatalytic proteolytical processing upon acidification.,similarity:Belongs to the peptidase S53 family.,subcellular location:Identified by mass spectrometry in melanosome fractions from stage I to stage IV.,tissue specificity:Detected in all tissues examined with highest levels in heart and placenta and relatively similar levels in other tissues.,